SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-90988"
 

Sökning: id:"swepub:oai:DiVA.org:oru-90988" > Prospective observa...

  • Forss, AndersKarolinska Institutet (författare)

Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE) : a 16-week follow-up

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-04-01
  • Taylor & Francis,2021
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-90988
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-90988URI
  • https://doi.org/10.1080/00365521.2021.1906946DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-175277URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:146340410URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agency:Janssen Cilag AB, Sweden  
  • Funding Agencies|Janssen Cilag AB, Sweden
  • BACKGROUND: Prospectively and systematically collected real-world data on the effectiveness of ustekinumab (anti-interleukin-12/23) for treating Crohn's disease (CD) are still limited.AIM: To assess the short-term real-world effectiveness of ustekinumab in Swedish patients with active CD.METHODS: Prospective multicentre study of adult CD patients initiating ustekinumab according to recommended doses at 20 hospitals, between January 2017 and November 2018. Data were collected through an electronic case report form (eCRF) linked to the Swedish Inflammatory Bowel Disease Registry (SWIBREG). The primary outcomes were clinical response (≥3-point-decrease of Harvey-Bradshaw index (HBI)) and remission (HBI ≤4 points) at week 16. Secondary outcomes included C-reactive protein (CRP) and haemoglobin (Hb) at baseline compared to week 16.RESULTS:  Of 114 included patients, 107 (94%) had failed >= 1 and 58 (51%) >= 2 biological agents (anti-tumour necrosis factor [aTNF] agents or vedolizumab). The 16-week ustekinumab retention rate was 105 (92%). Data on HBI at baseline were available for 96 patients. At week 16, response or remission was achieved in 38/96 (40%) patients (25/96 (26%) achieving clinical remission and 23/96 (24%) showing a clinical response). The median CRP concentration (N = 65) decreased from 6 to 4 mg/l (p = .006). No significant changes in Hb were observed. No incident malignancies or infections, requiring antibiotic treatment, were reported. CONCLUSIONS: In this nation-wide prospective real-world study of adult patients with CD, ustekinumab was associated with clinical effectiveness when administered according to clinical practice and seemed to represent a safe treatment option.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Clements, MarkKarolinska Institutet (författare)
  • Myrelid, PärLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US(Swepub:liu)parmy24 (författare)
  • Strid, HansDepartment of Internal Medicine, Södra Älvsborg Hospital, Borås, Sweden,Sodra Alvsborg Hosp, Sweden (författare)
  • Söderman, CharlotteKarolinska Institutet (författare)
  • Wagner, AgnieszkaDepartment of Internal Medicine, Blekinge Hospital, Karlskrona, Sweden,Blekinge Hosp, Sweden (författare)
  • Andersson, DavidDepartment of Internal Medicine, Danderyd University Hospital, Stockholm, Sweden,Danderyd Hosp, Sweden (författare)
  • Hjelm, FredrikJanssen Cilag AB, Stockholm, Sweden (författare)
  • Olén, OlaKarolinska Institutet (författare)
  • Ludvigsson, Jonas F.,1969-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Paediatrics, Örebro University Hospital, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA,Karolinska Inst, Sweden; Orebro Univ Hosp, Sweden; Univ Nottingham, England; Columbia Univ Coll Phys & Surg, NY USA(Swepub:oru)jsln (författare)
  • Halfvarson, Jonas,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Orebro Univ, Sweden(Swepub:oru)jshn (författare)
  • Karolinska InstitutetAvdelningen för kirurgi, ortopedi och onkologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Scandinavian Journal of Gastroenterology: Taylor & Francis56:6, s. 680-6860036-55211502-7708

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy